Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bogus HIV tests

This article was originally published in The Gray Sheet

Executive Summary

Alfa Scientific Designs is charged by the Federal Trade Commission with falsely representing that its Alfa HIV-1/2 Rapid Tests accurately detect HIV in its third legal action to date against a marketer of HIV tests. San Diego-based Alfa supplied the faulty HIV tests to Medimax, Inc., which was charged by the FTC in December for falsely representing on the Internet that its HIV tests accurately detected the disease (1"The Gray Sheet" Dec. 6, p. 24). On Nov. 17, FTC announced a settlement of charges against Las Vegas-based Cyberlinx Marketing related to claims over the Internet that its tests accurately detected HIV, including a ban from marketing any HIV test kits and repayment of sales proceeds. Alfa has agreed to a stipulated preliminary injunction that will halt all sales of its HIV tests. The complaint and stipulated preliminary injunction were filed Jan. 13 in the U.S. District Court for the Southern District of California
Advertisement

Related Content

Bogus HIV tests
Bogus HIV tests
Advertisement
UsernamePublicRestriction

Register

MT012844

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel